Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NuRx Pharmaceuticals has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor agonist NRX4204.
Subscribe to our email newsletter
The single-center study, which NuRx expects to complete in the fourth quarter of 2008, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company’s first drug candidate in clinical trials.
Harin Padma-Nathan, president and CEO of NuRx, said: “Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer. We intend to pursue the development of this compound as a treatment for both indications.”